Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 11Carcinoma, Non-Small-Cell Lung 8Gliosarcoma 7Breast Neoplasms 5Lung Neoplasms 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Central Nervous System Neoplasms 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Rectal Neoplasms 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Carcinoma 2Astrocytoma 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Untreated Childhood Anaplastic Astrocytoma 1To Evaluate the Safety of Taurine in Preventing Acute Radiation Skin Injury Induced by Adjuvant Radiotherapy in Breast Cancer Patients 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1

Interventions

Gemcitabine 4Oxaliplatin 3pembrolizumab 2tivozanib 1peposertib 1fludarabine 1durvalumab 1devimistat 1avelumab 1atezolizumab 1aldesleukin 1Temozolomide 1Specimen Handling 1Sorafenib 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Pemetrexed 1Leucovorin 1Irinotecan 1Interleukin-2 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Cannabidiol 1Bortezomib 1Biopsy 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × Radiation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡